Evidence map›Paper›PMID 26228542›Full record

ArticleBMC cancer2015

A novel cytosporone 3-Heptyl-4,6-dihydroxy-3H-isobenzofuran-1-one: synthesis; toxicological, apoptotic and immunomodulatory properties; and potentiation of mutagenic damage.

Rodrigo Juliano Oliveira, Stephanie Dynczuki Navarro, Dênis Pires de Lima, Alisson Meza, João Renato Pesarini, Roberto da Silva Gomes, Caroline Bilhar Karaziack, Mariana de Oliveira Mauro, Andréa Luiza Cunha-Laura, Antônio Carlos Duenhas Monreal and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Biosynthesis of Cytosporones in Leotiomycetous Filamentous Fungi.Journal of the American Chemical Society · 2024
    Article
  2. Article
  3. 3-Heptylidene-4,6-Dimethoxy-3Molecules (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Rodrigo Juliano OliveiraCentro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. rodrigo.oliveira@ufms.br.
Stephanie Dynczuki NavarroCentro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. stephaniedynczuki@hotmail.com.
Dênis Pires de LimaPrograma de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. denis.lima@ufms.br.
Alisson MezaPrograma de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. alisson_meza@hotmail.com.
João Renato PesariniCentro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. joao_rpe@hotmail.com.
Roberto da Silva GomesPrograma de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. robertogomes@ufgd.edu.br.
Caroline Bilhar KaraziackPrograma de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. carol.karaziack@gmail.com.
Mariana de Oliveira MauroCentro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. mari.mauro@hotmail.com.
Andréa Luiza Cunha-LauraCentro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. andrealclaura@gmail.com.
Antônio Carlos Duenhas MonrealCentro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. antonio.monreal@ufms.br.
Wanderson RomãoDepartamento de Química, Universidade Federal do Espírito Santo - UFES, Vitória, ES, Brazil. wandersonromao@gmail.com.
Valdemar Lacerda JúniorDepartamento de Química, Universidade Federal do Espírito Santo - UFES, Vitória, ES, Brazil. vljuniorqui@gmail.com.
Adilson BeatrizPrograma de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. adilson.beatriz@ufms.br.
Universidade Federal de Mato Grosso do Sul · BRUniversidade Federal do Espírito Santo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA large number of studies are attempting to identify alternative products from natural sources or synthesized compounds that effectively interact with cancer cells without causing adverse effects on healthy cells. Resorcinolic lipids are a class of bioactive compounds that possess anticancer activity and are able to interact with the lipid bilayer. Therefore, the objective of this study was to synthesize a novel resorcinolic lipid and test its biological proprieties.

methodsWe aimed to synthesize a novel resorcinolic lipid belonging to the class of cytosporones, AMS049 (3-Heptyl-4,6-dihydroxy-3H-isobenzofuran-1-one) and to evaluate the toxicity of two concentrations of this lipid (7.5 and 10 mg/kg) by determining its genotoxic, mutagenic, immunomodulatory, and apoptotic effects, as well as any biochemical and histopathological alterations in mice treated with cyclophosphamide. The results were analyzed by ANOVA followed by the Tukey test A . level of significance of p < 0.05 was adopted.

resultsThe new cytosporone AMS049 was synthesized in only three steps and in satisfactory yields. The results indicate that the compound is neither genotoxic nor mutagenic and does not alter biochemical parameters. The histological alterations observed in the liver and kidneys did not compromise the function of these organs. Histology of the spleen suggested immunomodulation, although no changes were observed in splenic phagocytosis or differential blood cell count. The results also show that AMS049 potentiates the mutagenic effect of the chemotherapy drug cyclophosphamide and that the combination induces apoptosis.

conclusionThese facts indicate a potential therapeutic application of this novel cytosporone as an important chemotherapeutic adjuvant.

Indexed as

AnimalsApoptosisBenzofuransCyclophosphamideDrug SynergismImmunologic FactorsKidneyLiverMaleMiceSpleenBenzofuransCyclophosphamideImmunologic Factors

Identifiers

PMID26228542
PMCPMC4520062
OpenAlexW2159009478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.